Hypertension is a major public health problem worldwide, affecting over 50 million individuals in the United States alone. The modern history of hypertension begins with the understanding of the cardiovascular system with the work of the physician William Harvey (1578-1657), who described the circulation of blood in his book De Motu Cordis. The English clergyman Stephen Hales made the first published measurement of blood pressure in 1733. Frederick Akbar Mahomed (1849-1884) made the first report of elevated blood pressure in a person without evidence of kidney disease. However, hypertension as a clinical entity came into being in 1896 with the invention of the cuff-based sphygmomanometer by Scipione Riva-Rocci. This apparatus has allowed the measurement of the blood pressure into the clinic. In 1905, Nikolai Korotkoff improved the technique by describing the Korotkoff sounds that are heard when the artery is auscultated with a stethoscope while the sphygmomanometer cuff is deflated.
The concept of essential hypertension ("hypertonic essential") was introduced in 1925 by the physiologist Otto Frank to describe elevated blood pressure for which no cause could be found. Over the several decades, increasing evidence accumulated from actuarial reports and longitudinal studies, such as the Framingham Heart Study. In the actuality, the term "inflammation" is used in the context of cardiovascular disease as a catchall referring to nonspecific phenomena, such as elevation of C-reactive protein. Most clinicians and investigators find this vague and difficult to understand. In this issue, we will attempt to address some of these puzzling questions.
In this way, several authors write on oxidative stress in the pathophysiology of target organ damage. G. Csányi and P. J. Pagano postulated that peptides mimicking the Nox4 Bloop and regions C-terminus on inhibit Nox4 activity and their findings suggest that Nox4 exists in a tightly assembled and active conformation which, unlike other Noxes In conclusion, the observed elevation in inflammatory parameters in subjects who subsequently go on to develop hypertension is particularly relevant and creates options for potential primary prevention strategies. A number of therapeutic agents have been identified which are able to influence this inflammatory process and positively influence cardiovascular outcomes.
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